RXRX

SEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 1

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,217,883

SEC source: 0001209191-21-065896 · doc4.xml · nonDerivative · entry 2

Li Dean Y · CIK 0001837016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,163

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-21-068911 · doc4a.xml · nonDerivative · entry 2

Li Dean Y · CIK 0001837016 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Dean Y. Li 2021 GRAT

Disclosed balance after: 1,330,900

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

F3 · ownership.direct: The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT.

SEC source: 0001209191-21-066254 · doc4.xml · nonDerivative · entry 2

Borgeson Blake · CIK 0001856094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,679,466

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.87 to $19.44 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-21-066254 · doc4.xml · nonDerivative · entry 1

Borgeson Blake · CIK 0001856094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,687,191

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $17.86 to $18.835 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-21-066261 · doc4.xml · nonDerivative · entry 2

Larson Tina Marriott · CIK 0001856414 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.13 to $19.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-21-066261 · doc4.xml · nonDerivative · entry 1

Larson Tina Marriott · CIK 0001856414 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,702

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.10 to $19.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-21-065896 · doc4.xml · nonDerivative · entry 1

Li Dean Y · CIK 0001837016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 591,637

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

SEC source: 0001209191-21-068911 · doc4a.xml · nonDerivative · entry 1

Li Dean Y · CIK 0001837016 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Dean Y. Li 2021 GRAT

Disclosed balance after: 1,344,374

F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.

F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

F3 · ownership.direct: The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT.

SEC source: 0001209191-21-059748 · doc4.xml · nonDerivative · entry 1

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,629

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-059743 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,169

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-059745 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,822

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-059741 · doc4.xml · nonDerivative · entry 1

Bogue Zachary · CIK 0001836157 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 781

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-059739 · doc4.xml · nonDerivative · entry 1

Borgeson Blake · CIK 0001856094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,689,091

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-059736 · doc4.xml · nonDerivative · entry 1

Li Dean Y · CIK 0001837016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 597,263

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045553 · doc4.xml · nonDerivative · entry 1

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,771

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045555 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,597

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045550 · doc4.xml · nonDerivative · entry 1

Borgeson Blake · CIK 0001856094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688,634

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045552 · doc4.xml · nonDerivative · entry 1

Li Dean Y · CIK 0001837016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596,720

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045551 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,193

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-045549 · doc4.xml · nonDerivative · entry 1

Bogue Zachary · CIK 0001836157 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295

F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

SEC source: 0001209191-21-038174 · doc4.xml · derivative · entry 2

Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 686,955

Underlying: Class A Common Stock · 45,045 shares

Expires 2030-03-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

SEC source: 0001209191-21-038174 · doc4.xml · nonDerivative · entry 1

Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 8

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,490,783 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F10 · shares: Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P.

F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F10 · derivative.underlying_shares: Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 7

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,825,883 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F9 · shares: Represents shares held of record by Lux Co-Invest Opportunities, L.P.

F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F9 · derivative.underlying_shares: Represents shares held of record by Lux Co-Invest Opportunities, L.P.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 6

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,578,653 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F8 · shares: Represents shares held of record by Lux Ventures IV, L.P.

F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F8 · derivative.underlying_shares: Represents shares held of record by Lux Ventures IV, L.P.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 5

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 10,279,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F8 · shares: Represents shares held of record by Lux Ventures IV, L.P.

F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F8 · derivative.underlying_shares: Represents shares held of record by Lux Ventures IV, L.P.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 4

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,287,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · shares: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P.

F7 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO.

F6 · balance_after: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 3

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · shares: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P.

F7 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 2

Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner

Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner

Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner

Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,187,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: 3,018,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,156,084 of these shares are held by Lux Ventures IV, L.P.

F5 · price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date.

F6 · balance_after: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P.

F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 9

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 0

Underlying: Class A Common Stock · 5,963,140 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F8 · derivative.exercise_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F8 · derivative.expiration_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F2 · ownership.nature: Consists of (i) 2,777,777 shares held of record by Fifteenth Investment Company LLC and (ii) 5,963,140 shares held of record by Thirty Fifth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 8

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 0

Underlying: Class A Common Stock · 745,392 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F8 · derivative.exercise_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F8 · derivative.expiration_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 7

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,738,824 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer.

F7 · price: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer.

F7 · derivative.exercise_date: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer.

F7 · derivative.expiration_date: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer.

F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 6

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 0

Underlying: Class A Common Stock · 3,578,653 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F6 · price: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F6 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F6 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 5

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 8,740,917

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F2 · ownership.nature: Consists of (i) 2,777,777 shares held of record by Fifteenth Investment Company LLC and (ii) 5,963,140 shares held of record by Thirty Fifth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 3

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 7,062,869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 2

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 6,317,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer.

F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 1

Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner

Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 3,578,653

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.

F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001209191-21-028022 · doc4.xml · derivative · entry 6

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,000

Underlying: Class A Common Stock · 525,000 shares

Expires 2030-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after April 23, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

F2 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.

SEC source: 0001209191-21-028022 · doc4.xml · derivative · entry 5

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 525,000 shares

Expires 2030-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after April 23, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

F2 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.

SEC source: 0001209191-21-028022 · doc4.xml · derivative · entry 4

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Class A Common Stock · 12,500 shares

Expires 2031-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option becomes exercisable upon the earlier of April 15, 2022 or the date of the Issuer's first annual meeting of stockholders.

F2 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.

SEC source: 0001209191-21-028022 · doc4.xml · derivative · entry 3

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2031-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option becomes exercisable upon the earlier of April 15, 2022 or the date of the Issuer's first annual meeting of stockholders.

F2 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.

SEC source: 0001209191-21-028022 · doc4.xml · nonDerivative · entry 2

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders.

F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.

SEC source: 0001209191-21-028022 · doc4.xml · nonDerivative · entry 1

CHAVEZ R. MARTIN · CIK 0001157983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders.

F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.

SEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 9

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

Underlying: Class B Common Stock · 1,500,000 shares

Expires 2030-12-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO.

SEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 8

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500,000 shares

Expires 2030-12-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO.

SEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 7

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,685 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO.

SEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 6

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,698 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.

F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO.

SEC source: 0001209191-21-028030 · doc4.xml · nonDerivative · entry 5

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Gibson Family Trust

Disclosed balance after: 150,000

F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO.

SEC source: 0001209191-21-028030 · doc4.xml · nonDerivative · entry 4

Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Gibson Family Trust

Disclosed balance after: 0

F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO.